NewsBenzingaWedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $40 Wedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $40 Benzinga 2026.11.10 15:33 (GMT+0) Open on Benzinga Other news ‘The Odds Are Almost Zero’: Scott Galloway Doesn’t See Jensen Huang Returning to Nvidia Analysis: Hyperliquid's Stock and Commodity Trading Revenue Grows 6x, Reducing Reliance on Crypto Market Grayscale: Multiple Factors Have Turned Crypto Valuations Oversold; Current Levels Are a Medium- to Long-Term Buying Opportunity for Bitcoin Bitcoin Lightning Network Developers Patch LND Flaw That Could Wipe Payment Records After Node Restart Canton Strategic Holdings Q3 Revenue of $3.05M, Net Loss Widens to $35.1M StablecoinX Q3 Revenue Reaches $478,000, Net Loss $100 Million
Analysis: Hyperliquid's Stock and Commodity Trading Revenue Grows 6x, Reducing Reliance on Crypto Market
Grayscale: Multiple Factors Have Turned Crypto Valuations Oversold; Current Levels Are a Medium- to Long-Term Buying Opportunity for Bitcoin
Bitcoin Lightning Network Developers Patch LND Flaw That Could Wipe Payment Records After Node Restart